NetScientific, the life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company ProAxsis (95% holding) has entered into a global licensing agreement with the University of Geneva and the University Hospital of Geneva, to develop new assays against fractures and other metabolic bone diseases, allowing for the rapid non‐invasive identification of subjects at high risk of osteoporotic fractures and potentially other metabolic bone dise ....
22 Feb 2021
WHI First Light: NetScientific (NSCI) - ProAxsis enters into a global licensing agreement
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WHI First Light: NetScientific (NSCI) - ProAxsis enters into a global licensing agreement
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
22 Feb 2021 -
Author:
John Cummins | Matthew Davis -
Pages:
4
NetScientific, the life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company ProAxsis (95% holding) has entered into a global licensing agreement with the University of Geneva and the University Hospital of Geneva, to develop new assays against fractures and other metabolic bone diseases, allowing for the rapid non‐invasive identification of subjects at high risk of osteoporotic fractures and potentially other metabolic bone dise ....